U.S. Fusion Biopsy Market Size & Outlook, 2023-2030
U.S. fusion biopsy market, 2018-2030 (US$M)
Related Markets
U.S. fusion biopsy market highlights
- The U.S. fusion biopsy market generated a revenue of USD 217.5 million in 2023 and is expected to reach USD 357.2 million by 2030.
- The U.S. market is expected to grow at a CAGR of 7.3% from 2024 to 2030.
- In terms of segment, transrectal was the largest revenue generating biopsy route in 2023.
- Transperineal is the most lucrative biopsy route segment registering the fastest growth during the forecast period.
Fusion biopsy market data book summary
| Market revenue in 2023 | USD 217.5 million |
| Market revenue in 2030 | USD 357.2 million |
| Growth rate | 7.3% (CAGR from 2023 to 2030) |
| Largest segment | Transrectal |
| Fastest growing segment | Transperineal |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Transrectal, Transperineal |
| Key market players worldwide | Koninklijke Philips NV, Hitachi Ltd, Esaote, Eigen, MedCom, Koelis, Focal Healthcare, UC Care |
Other key industry trends
- In terms of revenue, U.S. accounted for 34.8% of the global fusion biopsy market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. fusion biopsy market is projected to lead the regional market in terms of revenue in 2030.
- U.S. is the fastest growing regional market in North America and is projected to reach USD 357.2 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Fusion Biopsy Market Scope
Fusion Biopsy Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
U.S. fusion biopsy market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to fusion biopsy market will help companies and investors design strategic landscapes.
Transrectal was the largest segment with a revenue share of 83.17% in 2023. Horizon Databook has segmented the U.S. fusion biopsy market based on transrectal, transperineal covering the revenue growth of each sub-segment from 2018 to 2030.
The presence of efficient health coverage policies, low wait times for MRI scans, and growing awareness about targeted biopsy techniques are factors expected to drive the market during the forecast period. Random and targeted prostate biopsy techniques are covered by insurance providers in the U.S.
The cost of an MRI scan is also billed to the insurance provider, while the personal cost depends on the insurance policy and deductibles. Prostate cancer ranks second in terms of prevalence in men, with around 165,000 cases diagnosed each year in the U.S.
According to an NCBI report, over 700,000 to 1 million repeat biopsies are performed in the U.S. This has led to additional healthcare costs and discomfort for patients. By using a targeted biopsy technique, the number of repeat biopsies can be reduced significantly.
Reasons to subscribe to U.S. fusion biopsy market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of U.S. fusion biopsy market databook
-
Our clientele includes a mix of fusion biopsy market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. fusion biopsy market , including forecasts for subscribers. This country databook contains high-level insights into U.S. fusion biopsy market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
U.S. fusion biopsy market size, by biopsy route, 2018-2030 (US$M)
U.S. Fusion Biopsy Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
